The decision is based on an overall assessment of the previously reported positive phase IIa results in the FRACTAL-study, the opportunity for market approval and the market potential and payers’ willingness to pay for an approved product. The company has developed a development plan up until market approval, which includes a phase IIb study as a next step. Following with the decision regarding strategic direction, together with the assessment that the primary study objective can be met with the existing number of patients, the company will close the patient recruitment in the ongoing KANDOVA-study in ovarian cancer.

“We see significant opportunities for our candidate drugs in both cardiovascular diseases and cancer but by focusing the company’s resources to one therapeutic area, our opportunity to be successful will increase. Because of the high unmet medical need, expected high willingness from payers to pay and the significant market potential, in combination with our promising data from previous studies, we have now decided to focus on cardiovascular diseases and develop a new drug product to treat STEMI,” says Peter Selin, CEO at Kancera.